Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 0.81 |
| ▸ | ITGA4 | P13612 | 20/20 | 0.81 |
| ▸ | ITGB7 | P26010 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160746 | 0.90 | ITGB1 (0.71) | ITGB1ITGA4ITGB7 | |
| SCHEMBL24946050 | 0.90 | ITGA4 (1.00) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5165004 | 0.90 | ITGA4 (1.00) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5162530 | 0.89 | ITGA4 (0.81) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5162619 | 0.88 | ITGB1 (0.73) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5159929 | 0.86 | ITGB1 (0.82) | ITGB1ITGA4ITGB7 | |
| SCHEMBL15139762 | 0.84 | ITGB1 (0.63) | ITGB1ITGA4ITGB7 | |
| SCHEMBL15139760 | 0.84 | ITGB1 (0.63) | ITGB1ITGA4ITGB7 | |
| SCHEMBL15149417 | 0.84 | ITGB1 (0.62) | ITGB1ITGA4ITGB7 | |
| SCHEMBL15139900 | 0.84 | ITGB1 (0.62) | ITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237878-B1 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | EP | claimed |
| EP-1237878-A2 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-11 | — | — | EP | claimed |
| US-6380387-B1 | ANTIINFLAMMATORY AGENTS, ANTIASTHMATICS | HOFFMANN-LA ROCHE INC. | 2002-04-30 | — | — | US | claimed |
| WO-2001042225-A2 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-14 | — | — | WO | claimed |
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | GLAS USA LLC | 2023-02-02 | — | — | US | disclosed |
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | GLAS USA LLC | 2023-01-12 | — | — | US | disclosed |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | BT BIDCO LLC | 2020-10-15 | — | — | US | disclosed |
| EP-1237878-B1 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | EP | disclosed |
| EP-1237878-B1 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | EP | disclosed |
| EP-1237878-A2 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-11 | — | — | EP | disclosed |
| US-6380387-B1 | ANTIINFLAMMATORY AGENTS, ANTIASTHMATICS | HOFFMANN-LA ROCHE INC. | 2002-04-30 | — | — | US | disclosed |
| WO-2001042225-A2 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | ITGAL, ITGB2, ITGB1 | ITGB1 3/4885ITGA4 17/4885ITGB7 20/4885 |
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | ALPG, ALPP, FABP2 | ITGB1 1794/4885ITGA4 1529/4885ITGB7 1802/4885 |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | LRBA, CD47, FABP2 | ITGB1 706/4885ITGA4 546/4885ITGB7 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.